163 related articles for article (PubMed ID: 36088050)
21. A retrospective analysis of cisplatin/carboplatin plus paclitaxel in advanced or recurrent cervical cancer.
Song D; Kong W; Zhang T; Han C; Liu T; Jiao S; Chen J
J Obstet Gynaecol; 2019 Apr; 39(3):389-394. PubMed ID: 30663464
[TBL] [Abstract][Full Text] [Related]
22. Paclitaxel, Carboplatin, and Bevacizumab in Advanced and Recurrent Endometrial Carcinoma.
Rose PG; Ali S; Moslemi-Kebria M; Simpkins F
Int J Gynecol Cancer; 2017 Mar; 27(3):452-458. PubMed ID: 28187088
[TBL] [Abstract][Full Text] [Related]
23. Bevacizumab in Metastatic, Recurrent, or Persistent Cervical Cancer: The BC Cancer Experience.
Tinker AV; Fiorino L; O'Dwyer H; Kumar A
Int J Gynecol Cancer; 2018 Oct; 28(8):1592-1599. PubMed ID: 30247250
[TBL] [Abstract][Full Text] [Related]
24. Comparative analysis of doublet chemotherapy regimens plus bevacizumab in patients with recurrent ovarian cancer.
Khanmammadov NJ; Doğan İ; Okay NS; Azizy A; Saip P; Aydiner A
Medicine (Baltimore); 2024 Jan; 103(1):e36750. PubMed ID: 38181291
[TBL] [Abstract][Full Text] [Related]
25. A phase II study of postoperative concurrent carboplatin and paclitaxel combined with intensity-modulated pelvic radiotherapy followed by consolidation chemotherapy in surgically treated cervical cancer patients with positive pelvic lymph nodes.
Mabuchi S; Isohashi F; Yokoi T; Takemura M; Yoshino K; Shiki Y; Ito K; Enomoto T; Ogawa K; Kimura T
Gynecol Oncol; 2016 May; 141(2):240-246. PubMed ID: 26883141
[TBL] [Abstract][Full Text] [Related]
26. FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer.
Cohen MH; Gootenberg J; Keegan P; Pazdur R
Oncologist; 2007 Jun; 12(6):713-8. PubMed ID: 17602060
[TBL] [Abstract][Full Text] [Related]
27. A systematic review comparing cisplatin and carboplatin plus paclitaxel-based chemotherapy for recurrent or metastatic cervical cancer.
Lorusso D; Petrelli F; Coinu A; Raspagliesi F; Barni S
Gynecol Oncol; 2014 Apr; 133(1):117-23. PubMed ID: 24486604
[TBL] [Abstract][Full Text] [Related]
28. Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial.
Pignata S; Lorusso D; Joly F; Gallo C; Colombo N; Sessa C; Bamias A; Salutari V; Selle F; Frezzini S; De Giorgi U; Pautier P; Bologna A; Orditura M; Dubot C; Gadducci A; Mammoliti S; Ray-Coquard I; Zafarana E; Breda E; Favier L; Ardizzoia A; Cinieri S; Largillier R; Sambataro D; Guardiola E; Lauria R; Pisano C; Raspagliesi F; Scambia G; Daniele G; Perrone F;
Lancet Oncol; 2021 Feb; 22(2):267-276. PubMed ID: 33539744
[TBL] [Abstract][Full Text] [Related]
29. The activity of carboplatin and paclitaxel for recurrent cervical cancer after definitive radiotherapy.
Mabuchi S; Morishige K; Fujita M; Tsutsui T; Sakata M; Enomoto T; Kimura T
Gynecol Oncol; 2009 May; 113(2):200-4. PubMed ID: 19268342
[TBL] [Abstract][Full Text] [Related]
30. Improved survival with bevacizumab in advanced cervical cancer.
Tewari KS; Sill MW; Long HJ; Penson RT; Huang H; Ramondetta LM; Landrum LM; Oaknin A; Reid TJ; Leitao MM; Michael HE; Monk BJ
N Engl J Med; 2014 Feb; 370(8):734-43. PubMed ID: 24552320
[TBL] [Abstract][Full Text] [Related]
31. Patient, disease, and survival outcomes for stage IB to stage IV cervical cancer-A population study.
Wang C; Lester B; Huang L; Sun S; Ko JJ
Womens Health (Lond); 2023; 19():17455057231164551. PubMed ID: 37052298
[TBL] [Abstract][Full Text] [Related]
32. Bevacizumab with dose-dense paclitaxel/carboplatin as first-line chemotherapy for advanced ovarian cancer.
Zhang L; Zhou Q
Eur J Pharmacol; 2018 Oct; 837():64-71. PubMed ID: 30059681
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of bevacizumab in Turkish patients with metastatic and recurrent cervical cancer.
Ercelep Ö; Tataroğlu D; Özçelik M; Sürmeli H; Değirmenci M; İnanç M; Aliustaoğlu M; Gümüş M
Turk J Obstet Gynecol; 2020 Jun; 17(2):123-127. PubMed ID: 32850187
[TBL] [Abstract][Full Text] [Related]
34. Prognostic models to predict survival in non-small-cell lung cancer patients treated with first-line paclitaxel and carboplatin with or without bevacizumab.
Hoang T; Dahlberg SE; Sandler AB; Brahmer JR; Schiller JH; Johnson DH
J Thorac Oncol; 2012 Sep; 7(9):1361-8. PubMed ID: 22843087
[TBL] [Abstract][Full Text] [Related]
35. Impact of Adding Bevacizumab to Paclitaxel + Carboplatin for Platinum-Sensitive Recurrent Epithelial Ovarian Cancer: A Propensity Score Matching Analysis.
Hirasawa T; Machida H; Iida T; Ikeda M; Shida M; Mikami M
Tokai J Exp Clin Med; 2018 Sep; 43(3):85-89. PubMed ID: 30191541
[TBL] [Abstract][Full Text] [Related]
36. Patient profiles, treatment patterns, and outcomes among persistent, recurrent, or metastatic cervical cancer patients under routine care in the United States.
Gokhale M; Yu R; Monberg M; Tekin C; Chen L; DeClue RW; Knapp K; Lal LS
Cancer Treat Res Commun; 2023; 36():100726. PubMed ID: 37301127
[TBL] [Abstract][Full Text] [Related]
37. PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer.
Patel JD; Socinski MA; Garon EB; Reynolds CH; Spigel DR; Olsen MR; Hermann RC; Jotte RM; Beck T; Richards DA; Guba SC; Liu J; Frimodt-Moller B; John WJ; Obasaju CK; Pennella EJ; Bonomi P; Govindan R
J Clin Oncol; 2013 Dec; 31(34):4349-57. PubMed ID: 24145346
[TBL] [Abstract][Full Text] [Related]
38. BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma.
Kim KB; Sosman JA; Fruehauf JP; Linette GP; Markovic SN; McDermott DF; Weber JS; Nguyen H; Cheverton P; Chen D; Peterson AC; Carson WE; O'Day SJ
J Clin Oncol; 2012 Jan; 30(1):34-41. PubMed ID: 22124101
[TBL] [Abstract][Full Text] [Related]
39. Comparative Effectiveness of Carboplatin/Pemetrexed With Versus Without Bevacizumab for Advanced Nonsquamous Non-Small Cell Lung Cancer.
Bagley SJ; Talento S; Mitra N; Meropol NJ; Cohen RB; Langer CJ; Vachani A
J Natl Compr Canc Netw; 2019 May; 17(5):469-477. PubMed ID: 31085759
[TBL] [Abstract][Full Text] [Related]
40. Response to Combination Chemotherapy With Paclitaxel/Ifosfamide/Platinum Versus Paclitaxel/Platinum for Patients With Metastatic, Recurrent, or Persistent Carcinoma of the Uterine Cervix: A Retrospective Analysis.
Choi HJ; Paik ES; Choi CH; Kim TJ; Lee YY; Lee JW; Bae DS; Kim BG
Int J Gynecol Cancer; 2018 Sep; 28(7):1333-1341. PubMed ID: 30045137
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
